{
    "organizations": [],
    "uuid": "7f92c1d4c78a171e7af577c229ad976ede71b1eb",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-osmotica-pharmaceutical-says-fda-a/brief-osmotica-pharmaceutical-says-fda-approves-osmolex-er-for-treatment-of-parkinsons-disease-idUSASB0C69W",
    "ord_in_thread": 0,
    "title": "BRIEF-Osmotica Pharmaceutical Says FDA Approves OSMOLEX ER For Treatment Of Parkinson’s Disease",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "Feb 19 (Reuters) - Osmotica Pharmaceutical US LLC:\n* FDA APPROVES OSMOTICA PHARMACEUTICAL’S ONCE-DAILY OSMOLEX ER™ (AMANTADINE) EXTENDED-RELEASE TABLETS FOR THE TREATMENT OF PARKINSON’S DISEASE AND DRUG-INDUCED EXTRAPYRAMIDAL REACTIONS IN ADULTS Source text for Eikon:\n ",
    "published": "2018-02-20T02:03:00.000+02:00",
    "crawled": "2018-02-20T14:13:15.000+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "feb",
        "reuters",
        "osmotica",
        "pharmaceutical",
        "u",
        "llc",
        "fda",
        "approves",
        "osmotica",
        "pharmaceutical",
        "osmolex",
        "amantadine",
        "tablet",
        "treatment",
        "parkinson",
        "disease",
        "extrapyramidal",
        "reaction",
        "adult",
        "source",
        "text",
        "eikon"
    ]
}